# Pyridorin in Diabetic Nephropathy

> **NCT02156843** · PHASE3 · TERMINATED · sponsor: **NephroGenex, Inc.** · enrollment: 328 (actual)

## Conditions studied

- Diabetic Nephropathy
- Diabetic Kidney Disease

## Interventions

- **DRUG:** Pyridorin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02156843
- **Lead sponsor:** NephroGenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-03
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2016-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156843, "Pyridorin in Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02156843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*